Levosimendan treatment of myocardial depression in sepsis: A case series and review of the literature;Tratamiento de la depresión miocárdica por sepsis con levosimendan. Serie de casos y revisión de la bibliografía

Medicina Interna de Mexico

Volumn 26, Issue 4, 2010, Pages 324-336

  Rincón Villegas, Jaime Aquiles ^a   Martínez Monter, Julisa ^a   Monteón Batalla, Ignacio ^a   Huggo Córdova Pluma, Victor ^a  

^a UNIVERSIDAD LA SALLE   (Mexico)

Author keywords

Calcium sensitizers; Heart failure; Inotropes; Levosimendan; Septic cardiomyopathy; Septic shock

Indexed keywords

AMIKACIN; ANIDULAFUNGIN; CATECHOLAMINE; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CREATININE; ERTAPENEM; LACTIC ACID; LEVOFLOXACIN; LEVOSIMENDAN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NORADRENALIN; OSELTAMIVIR; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; VASOACTIVE AGENT; VASOPRESSIN;

ADULT; AGED; APACHE; ARTICLE; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM PRESSURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART STROKE VOLUME; HUMAN; LACTATE BLOOD LEVEL; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MYOCARDIAL DISEASE; PULMONARY ARTERY OCCLUSION PRESSURE; SEPSIS; SEPTIC SHOCK; SYSTEMIC VASCULAR RESISTANCE;

EID: 77956925701     PISSN: 01864866     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure: mechanisms of action and recent clinical developments. N Engl J Med 1986;314:349-358. (Pubitemid 16166262)
2. Slawsky MT, Colucci WS, Gottlieb SS. Acute hemodynamic and clinical effects of Levosimendan in patients with severe heart failure. Circulation 2000;102: 2222-2227.
3. Lee JC, Downing SE. Cyclic AMP and the pathogenesis of myocardial injury. Res Commun Chem Pathol Pharmacol 1980;27:305-318.
4. Packer M, Leier CV. Survival in congestive heart failure during treatment with drugs with positive inotropic actions. Circulation 1987;75:(Suppl 4):55-63.
5. Ferrick KJ, Fein SA, Ferrick AM. Effect of milrinone on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1990;66:431-434.
6. Hasenfuss G, Holubarsch C, Heiss HW. Myocardial energetic in patients with dilated cardiomyopathy. Circulation 1989;80:51-64.
7. Haikala H, Pollesello P. Calcium sensitivity enhancers. Drugs 2000;3:1199-1205.
8. Dies F, Krell MJ, Whitlow P. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986;74(Suppl 2):389.
9. Ferrick KJ, Fein SA, Ferrick AM. Effect of milrinone on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1990;66:431-434.
10. Felker GM, Benza RL, Chandler AB. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003;41: 997-1003.
11. Abraham WT, Adams KF, Fonarow GC. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications. An analysis from the acute decompensated heart failure national registry (ADHERE). J Am Coll Cardiol 2005;46:57-64.
12. Hasenfuss G, Pieske B, Castell M. Influence of the novel inotropic agent levosimedan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-2147.
13. Janssen PM, Datz N, Zeitz O. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 2000;404:191-199.
14. Pagel PS, McGough MF, Hettrick DA. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 1997;29:563-573.
15. Tachibana H, Cheng H, Ukai T. Levosimendan improves left ventricular systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 2005; 288:H914-H922
16. Hasenfuss G, Pieske B, Kretschmann B, et al. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetic. J Cardiovasc Pharmacol 1995;26(Suppl 1): S45-51.
17. Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 1995;26:S10-19.
18. Gheorghiade M, Terrlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005;96:68-73.
19. Yokoshiki H, Katsube Y, Sunagawa M, et al. Levosimendan, a novel Ca sensitizer, activates the glibenclamide sensitive K channel in rat arterial myocytes. Eu J Pharmacol 1997;333:249-259. (Pubitemid 27387398)
20. Pataricza J, Hohn J, Petri A, et al. Comparison of the vasorelaxing effect of cormakalim and the new inodilator, Levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000;52:213-217.
21. Kaheinen P, Pollesello P, Levijoki J, et al. Levosimendan increases diastolic coronary flow in isolated guinea pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001;37:367-374.
22. Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous Levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005;111:1504-1509.
23. Maytin M, Colucci WS. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005; 96(Suppl):26G-31G.
24. Nieminen MS, Akkila J, Hesenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of Levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-1912.
25. Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996;3:243-249.
26. Sasayama S, Matsumori A, Kihara Y. New insights into the pathophysiological role for cytokines in heart failure. Cardiovasc Res 1999;42:557-564.
27. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241.
28. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-1206.
29. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spill-over in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998; 31:391-398.
30. Plenz G, Song ZF, Tjan TDT, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail 2001;3:415-421.
31. Parissis JT, Adamopoulos S, Antoniades C, et al. Effects of Levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309-1312. (Pubitemid 38595693)
32. Avgeropoulou C, Andeadou I, Sophia Markantonis-Kyroudis T, et al. The Ca 2+ sensitizer Levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eu J Heart Fail 2005;7: 82-87.
33. Kyrzopoulos S, Adamapoulos S, Parissis JT, et al. Levosimendan reduces plasma B type natriuretic peptide and interleukin 6, and improves central hemodynamic in severe heart failure patients. Int J Cardiol 2005;99:409-413.
34. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311: 819-823.
35. Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activitiy in the failing human heart. J Am Coll Cardiol 1995; 26: 1257-1263.
36. Bristow MR, Krause-Steinrauf H, Nuzzo R, et al. Effect of baseline or changes in adrenergic activitiy on clinical outcomes in the beta blocker evaluation of survival trial. Circulation 2004;110: 1437-1442.
37. Nicklas JM, Monsur JC, Bleske BE. Effects of intravenous Levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol 1999;83:112-115.
38. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-391.
39. Moertl D, Berger R, Huelsmann M, et al. Short term effects of Levosimendan and prostaglandin E1 on hemodynamic parameters and B type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail 2005;7:1156-1163.
40. Parissis JT, Panou F, Farmakis D, et al. Effects of Levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005;96:423-426.
41. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, et al. Coronary vasorelaxant effect of Levosimendan, a new inodilator with calcium sensitizing properties. J Cardiovasc Pharmacol 1998;31:741-749.
42. Kaheinen P, Pollesello P, Levijoki J, et al. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001;37:367-374.
43. Ukkonen H, Sarastre M, Akkila J, et al. Myocardial efficiency during Levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000;68:522-531.
44. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous Levosimendan compared with dobutamine in severe low output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002;360:196-202.
45. Kivikko M, Antila S, Eha J, et al. Pharmacokinetics of Levosimendan and its metabolites during and after a 24 hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002;40:465-471. (Pubitemid 35153452)
46. Kivikko M, Antila S, Eha J, et al. Pharmacodynamics and safety of a new calcium sensitizer, Levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002;42:43-51. (Pubitemid 34038369)
47. Zairis MN, Apostolatos C, Anastasiadis P. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results from the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure Study (CASINO). (Abstract). J Am Coll Cardiol 2004; 43: (Suppl 1):206A-207A.
48. Packer M, Colucci WS, Fisher L. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with Levosimendan in the REVIVE-1 study. (Abstract). J Card Fail 2003;9:S61.
49. Packer M. The Randomized multicenter Evaluation of Intravenous Levosimendan Efficacy-2 (REVIVE-2) trial. Late-breaking Clinical Trials. American Heart Association, Annual Scientific Session, Dallas, TX, 13-16 November 2005.
50. Mebazaa A, Cohen-Solal A, Kleber F. Study design of a mortality trial with intravenous Levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure. (Abstract). Critical Care 2004;8:(Suppl 1):87.
51. Mebazaa A. The SURvival of Patients with Acute Heart Failure in Need of IntraVEnous Inotropic Support (SURVIVE) trial. Late-breaking Clinical Trials. American Heart Association, Annual Scientific Session, Dallas, TX, 13-16 November 2005.
52. Lilleberg J, Nieminem MS, AkkilaJ, et al. Effects of a new calcium sensitizer, Levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after CABG. Eu Heart J 1998; 19:660-668.
53. Plochl W, Rajek A. The use of the novel calcium sensitizer Levosimendan in critically ill patients. Anaesth Inensive Care 2004;32:471-475.
54. Nijhawan N, Nicolosi A, Montgomery MW, et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34:219-228.
55. Barisin S, Husedzinovic I, Sonicki Z, et al. Levosimendan in off-pump coronary artery bypass: a four times masked controlled study. J Cardiovasc Pharmacol 2004;44:703-708.
56. 2+ sensitizer Levosimendan. Med Klein 2004;99:742-746.
57. Benlolo S, Lefoll C, Katchatouryan V, et al. Successful use of Levosimendan in a patient with peripartum cardiomyopathy. Anaesth Analg 2004;98:822-824.
58. Franco F, Monteiro P, Correia J. Levosimendan is safe and effective in patients with severe low cardiac output heart failure and critical hypotension. (Abstract) J Am Coll Cardiol 2004;43:191A.
59. McLean A, Huang S, Stewart D, et al. Efficacy of Levosimendan in shock. (Abstract) Crit Care 2004;6:83.
60. Turani F, Aurisicchio P, D'Ercole P. Hemodynamic and volumetric response to Levosimendan in critical care patients. (Abstract) Crit Care 2004;6:84.
61. Delle Karth G, Buberl A, Geppert A, et al. Hemodynamic effects of a continuous infusion of Levosimendan in critically ill patients with cardiogénico shock requiring catecholamines. Acta Anaesth Scan 2003;47:1251-1256.
62. Parrillo JE. The cardiovascular pathophysiology of sepsis. Ann Rev Med 1989;40:469-485.
63. Muller-Werdan U, Reithmann C, Werdan K. Cytokines and the heart: Molecular mechanisms of septic cardiomyopathy. Austin: Landes Bioscience, 1996.
64. Schmidt H, Muller-Werdan U, Werdan K. The consequences of cardiac autonomic dysfunction in multiple organ dysfunction syndrome. In: Vincent JL (ed) 2008 Yearbook of Intensive Care and Emergency Medicine. Heidelberg: Springer, 2008;p:55-64.
65. Werdan K, Oelke A, Muller-Werdan U. Myocardial depression or septic cardiomyopathy? In: Vincent JL (ed) 2009 Yearbook of Intensive Care and Emergency Medicine. Heidelberg: Springer, 2009;p:183-194.
66. Pilz G, McGinn P, Boekstegers P, et al. Pseudomonas sepsis does not cause more severe cardiovascular dysfunction in patients than non-pseudomonas sepsis. Circ Shock 1994;42:174-182.
67. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group On Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-276.
68. Oldner A, Konrad D, Weitzberg E, et al. Effects of Levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 2001;29:2185-2193.
69. Gazmuri RJ, Kolarova JD, Ayoub IM. Inotropic options for postresuscitation myocardial dysfunction. Crit Care Med 2005;33:668-669.
70. Noto A, Giacomini M, Palandi A, et al. Levosimendan in septic cardiac failure. Intensive Care Med 2005;31:164-65.
71. Matejovic M, Krouzecky A, Radej J, et al. Successful reversal of resistant hypodynamic septic shock with Levosimendan. Acta Anaesthesiol Scand 2005;49:127.
72. Kumar A, Thota V, Dee L, et al. Tumor necrosis factor-alpha and interleukin 1-beta are responsible for depression of in vitro myocardial cell contractility induced by serum from humans with septic shock. J Exp Med 1996;183:949-958.
73. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in adult mammalian heart. J Clin Invest 1993;92:2303-2312.
74. 2+ and contractility on isolated adult rabbit ventricular myocytes. Am J Physiol 1996;271(Suppl 4):H 1499-1505 g.
75. Zager RA, Johnson AC, Lund S, et al. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Renal Physiol 2006;290:1453-1462.
76. 2+ sensitizer Levosimendan improves oxidative damage, BNP and proinflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamina. Eur J Heart Failure 2005;7:882-887.
77. Silverman HJ, Peneranda R, Orens JB, et al. Impaired beta-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: Association with myocardial hyporesponsiveness to catecholamines. Crit Care Med 1993;21:31-39.
78. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
79. Packer M. The search for the ideal positive inotropic agent. N Eng J Med 1993;329:201-202.
80. Morelli A, De Castro S, Teboul JL, et al. Effects of Levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005;31:638-644.
81. Morelli A, Teboul JL, Maggiore S, et al. Effects of Levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: A pilot study. Crit Care Med 2006;34:2287-2293.